In particular, SGLT2 inhibitors, function as another hemodynamic target, and nsMRAs, interrupt aldosterone signaling via the mineralocorticoid receptor, which undergoes over activation in DKD, have provided significant hope and continue to extend kidney life and the overall lifespan for patients with DKD. This evidence concerns the gene NR3C2 and diabetic kidney disease.